Literature DB >> 9231152

CD44 and the adhesion of neoplastic cells.

Z Rudzki1, S Jothy.   

Abstract

CD44 is a family of transmembrane glycoproteins that act mainly as a receptor for hyaluronan. It can also bind some other extracellular matrix ligands (chondroitin sulphate, heparan sulphate, fibronectin, serglycin, osteopontin) with lower affinity. CD44 is encoded by a single gene containing 20 exons, 10 of which (v1-v10) are variant exons inserted by alternative splicing. The standard, ubiquitously expressed isoform of CD44, does not contain sequences encoded by these variant exons. Numerous variant isoforms of CD44 containing different combinations of exons v1-v10 inserted into the extracellular domain can be expressed in proliferating epithelial cells and activated lymphocytes. CD44 plays a significant role in lymphocyte homing. Both alternative splicing and glycosylation influence receptor function of the molecule, usually reducing its affinity to hyaluronan. The cytoplasmic domain of CD44 communicates with the cytoskeleton via ankyrin and proteins belonging to the ezrin-moesin-radixin family. Relatively little is known about the intracellular events following interactions of CD44 with its ligands. Some variant isoforms, especially those containing sequences encoded by v6-v10, are overexpressed in both human and animal neoplasms. In a rat pancreatic adenocarcinoma model one of the variant CD44 isoforms was proved to be determinant in the metastatic process. For some human neoplasms (carcinomas of the digestive tract, non-Hodgkin's lymphomas, thyroid carcinomas, and others) correlations have been made between the particular pattern of CD44 variants produced by neoplastic cells and clinicopathological parameters of tumours, such as grade, stage, presence of metastases, and survival. In vitro studies indicate that modifications of CD44 expression result in different ligand recognition and influence cell motility, invasive properties, and metastatic potential of experimental tumours. Investigation of CD44 neoexpression can be useful both in early cancer diagnosis and in predicting tumour behaviour. It can also contribute to better understanding of molecular mechanisms leading to neoplastic transformation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231152      PMCID: PMC379585          DOI: 10.1136/mp.50.2.57

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  139 in total

1.  Monoclonal antibody to a human brain-granulocyte-T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat.

Authors:  R Dalchau; J Kirkley; J W Fabre
Journal:  Eur J Immunol       Date:  1980-10       Impact factor: 5.532

2.  Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors.

Authors:  K Yoshida; J Bolodeoku; T Sugino; S Goodison; Y Matsumura; B F Warren; T Toge; E Tahara; D Tarin
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

3.  Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies.

Authors:  G Salles; M Zain; W M Jiang; V A Boussiotis; M A Shipp
Journal:  Blood       Date:  1993-12-15       Impact factor: 22.113

4.  Restoration of CD44H expression in colon carcinomas reduces tumorigenicity.

Authors:  K K Tanabe; I Stamenkovic; M Cutler; K Takahashi
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

5.  Prevention of tumor metastasis formation by anti-variant CD44.

Authors:  S Seiter; R Arch; S Reber; D Komitowski; M Hofmann; H Ponta; P Herrlich; S Matzku; M Zöller
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

6.  Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis.

Authors:  V B Lokeshwar; L Y Bourguignon
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

7.  New CD44 splice variants associated with human breast cancers.

Authors:  N Iida; L Y Bourguignon
Journal:  J Cell Physiol       Date:  1995-01       Impact factor: 6.384

8.  ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons.

Authors:  S Tsukita; K Oishi; N Sato; J Sagara; A Kawai; S Tsukita
Journal:  J Cell Biol       Date:  1994-07       Impact factor: 10.539

9.  CD44H regulates tumor cell migration on hyaluronate-coated substrate.

Authors:  L Thomas; H R Byers; J Vink; I Stamenkovic
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

10.  CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor.

Authors:  K L Bennett; D G Jackson; J C Simon; E Tanczos; R Peach; B Modrell; I Stamenkovic; G Plowman; A Aruffo
Journal:  J Cell Biol       Date:  1995-02       Impact factor: 10.539

View more
  33 in total

1.  Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices.

Authors:  K Maaser; K Wolf; C E Klein; B Niggemann; K S Zänker; E B Bröcker; P Friedl
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

2.  Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma.

Authors:  Samantha J Davis; Vasu Divi; John H Owen; Carol R Bradford; Thomas E Carey; Silvana Papagerakis; Mark E P Prince
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-12

3.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

Review 4.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

5.  Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis.

Authors:  Yue Leng; Ammara Abdullah; Michael K Wendt; Sarah Calve
Journal:  Matrix Biol       Date:  2018-08-18       Impact factor: 11.583

6.  miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.

Authors:  Jon C Henry; Jong-Kook Park; Jinmai Jiang; Ji Hye Kim; David M Nagorney; Lewis R Roberts; Soma Banerjee; Thomas D Schmittgen
Journal:  Biochem Biophys Res Commun       Date:  2010-11-03       Impact factor: 3.575

7.  Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.

Authors:  Dan Peer; Rimona Margalit
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

8.  The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells.

Authors:  Hirokatsu Osawa; Christian A Smith; Young Shin Ra; Paul Kongkham; James T Rutka
Journal:  Neuro Oncol       Date:  2008-12-16       Impact factor: 12.300

9.  Analysis of the expression of hyaluronan in intraductal and invasive carcinomas of the breast.

Authors:  Maria Daniela Corte; Luis Ovidio González; Sara Junquera; Miguel Bongera; Maria Teresa Allende; Francisco José Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-07       Impact factor: 4.553

10.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.